MARTINSRIED/MUNICH, Germany, April 13, 2007 -- Today the biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announced the initiation of a phase II trial of the drug candidate EndoTAGTM-1 for the treatment of triple receptor negative breast cancer. The objective of the trial is to investigate the efficacy of EndoTAGTM-1 against this highly aggressive type of cancer, and to collect safety data. 135 patients are to be enrolled in this trial which will be conducted by more than 20 centers in different European countries. The final results of the trial are expected for 2009.
